Managed Access Program (MAP) to Provide Access to Eltrombopag, for Treatment of Patients With Medically Significant Thrombocytopenia
Latest Information Update: 09 Feb 2024
At a glance
- Drugs Eltrombopag (Primary)
- Indications Aplastic anaemia; Idiopathic thrombocytopenic purpura; Thrombocytopenia
- Focus Expanded access; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 12 Apr 2021 New trial record